Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Cellceutix Corporation has created a new chemical entity for the treatment of psoriasis,
termed Prurisol™, which is an ester of abacavir. This first-in-human study of Prurisol
(abacavir acetate) is being performed to evaluate the pharmacokinetics, safety and tolerance
of a single oral doses of Prurisol administered to healthy volunteers and the bioequivalence
to abacavir sulfate (Ziagen). This study will be followed by a 505(b)(2) Phase 2 trial in
patients with moderate to severe plaque psoriasis.